Don't Miss


How are HTA reviews impacting pharma's innovative drug ambitions in major markets?

HTA reviews are shaping the competitive landscape for innovative drugs in non-US markets. Between January 2016 and June 2018, 95 innovative medicines were approved in the US—but only 67 have been launched in a major market elsewhere. Understanding which companies and products are being impacted is critical competitive intelligence. Which companies are involved? What products have made the grade and where? For answers turn to Innovative Drugs: Mapping the Pricing and Reimbursement Landscape. Comprising a detailed report and usable data set in Microsoft ExcelTM, this granular analysis exposes—at a product level—the pricing, reimbursement and HTA status of innovative drugs in Australia, Canada, France, Germany and the UK.

Find out more >>

Insight, Analysis and Views

Teva reaches $85-million settlement with Oklahoma to resolve opioid claims

My News

Upgrade your subscription to get more features!

Conference News

Latest News

StoryWatch